Table 3

Results of parallel multivariate analysis of ZAP70 status, CD38 status, IgVH status, FISH status for 17p and 11q combined or alternatively TP53 exon 2-10 mutations, Rai stage, and SNP 6.0 array–based lesion cutoffs on OS in previously untreated patients with CLL (n = 187)

Variablen/NHRCIPVariablen/NHRCIP
SNP 6.0 array genomic lesions ≥ 2 vs < 2 65/122 2.9 1.03-8.2 .04 SNP 6.0 array genomic lesions ≥ 2 vs < 2 65/122 2.9 1.06-7.9 .03 
Del17p or del11q present vs not 28/159 2.1 0.7-6.7 .19 TP53 exon 2-10 mutated vs not 22/165 2.5 0.9-7.1 .09 
Rai stage I-IV vs 0 90/97 1.3 0.6-3.2 .53 Rai stage I-IV vs 0 90/97 1.3 0.6-3.1 .54 
ZAP70 ≥ 20% vs < 20% 80/107 0.9 0.3-2.5 .85 ZAP70 ≥ 20% vs < 20% 80/107 0.9 0.3-2.5 .82 
IgVH UM vs M 79/108 1.6 0.6-4.5 .39 IgVH UM vs M 79/108 1.9 0.7-5.2 .23 
CD38 ≥ 30% vs < 30% 45/142 0.4 0.1-1.3 .1 CD38 ≥ 30% vs < 30% 45/142 0.4 0.1-1.4 .14 
 
SNP 6.0 array genomic lesions ≥ 3 vs < 3 28/159 4.3 1.4-13.4 .01 SNP 6.0 array genomic lesions ≥ 3 vs < 3 28/159 4.2 1.3-13.6 < .01 
Del17p or del11q present vs not 28/159 1.8 0.5-6.6 .38 TP53 exon 2-10 mutated vs not 22/165 1.7 0.5-6 .37 
Rai stage I-IV vs 0 90/97 1.3 0.5-3 .59 Rai stage I-IV vs 0 90/97 1.3 0.5-3 .6 
ZAP70 ≥ 20% vs < 20% 80/107 0.7 0.3-2 .54 ZAP70 ≥ 20% vs < 20% 80/107 0.8 0.3-2.1 .61 
IgVH UM vs M 79/108 1.8 0.6-5.1 .29 IgVH UM vs M 79/108 1.9 0.7-5.3 .19 
CD38 ≥ 30% vs < 30% 45/142 0.3 0.1-1.1 .06 CD38 ≥ 30% vs < 30% 45/142 0.3 0.1-1.2 .08 
 
SNP 6.0 array genomic lesions ≥ 4 vs < 4 17/170 19.5 3.9-97 < .01 SNP 6.0 array genomic lesions ≥ 4 vs < 4 17/170 18 4-81 < .01 
Del17p or del11q present vs not 28/159 0.8 0.2-3.7 .78 TP53 exon 2-10 mutated vs not 22/165 0.9 0.3-3.3 .89 
Rai stage I-IV vs 0 90/97 1.1 0.5-2.7 .8 Rai stage I-IV vs 0 90/97 1.1 0.5-2.7 .8 
ZAP70 ≥ 20% vs < 20% 80/107 0.6 0.2-1.7 .3 ZAP70 ≥ 20% vs < 20% 80/107 0.6 0.2-1.6 .26 
IgVH UM vs M 79/108 1.2 0.4-3.8 0.78 IgVH UM vs M 79/108 1.2 0.4-3.8 .8 
CD38 ≥ 30% vs < 30% 45/142 0.4 0.1-1.6 .2 CD38 ≥ 30% vs < 30% 45/142 0.4 0.1-1.5 .2 
Variablen/NHRCIPVariablen/NHRCIP
SNP 6.0 array genomic lesions ≥ 2 vs < 2 65/122 2.9 1.03-8.2 .04 SNP 6.0 array genomic lesions ≥ 2 vs < 2 65/122 2.9 1.06-7.9 .03 
Del17p or del11q present vs not 28/159 2.1 0.7-6.7 .19 TP53 exon 2-10 mutated vs not 22/165 2.5 0.9-7.1 .09 
Rai stage I-IV vs 0 90/97 1.3 0.6-3.2 .53 Rai stage I-IV vs 0 90/97 1.3 0.6-3.1 .54 
ZAP70 ≥ 20% vs < 20% 80/107 0.9 0.3-2.5 .85 ZAP70 ≥ 20% vs < 20% 80/107 0.9 0.3-2.5 .82 
IgVH UM vs M 79/108 1.6 0.6-4.5 .39 IgVH UM vs M 79/108 1.9 0.7-5.2 .23 
CD38 ≥ 30% vs < 30% 45/142 0.4 0.1-1.3 .1 CD38 ≥ 30% vs < 30% 45/142 0.4 0.1-1.4 .14 
 
SNP 6.0 array genomic lesions ≥ 3 vs < 3 28/159 4.3 1.4-13.4 .01 SNP 6.0 array genomic lesions ≥ 3 vs < 3 28/159 4.2 1.3-13.6 < .01 
Del17p or del11q present vs not 28/159 1.8 0.5-6.6 .38 TP53 exon 2-10 mutated vs not 22/165 1.7 0.5-6 .37 
Rai stage I-IV vs 0 90/97 1.3 0.5-3 .59 Rai stage I-IV vs 0 90/97 1.3 0.5-3 .6 
ZAP70 ≥ 20% vs < 20% 80/107 0.7 0.3-2 .54 ZAP70 ≥ 20% vs < 20% 80/107 0.8 0.3-2.1 .61 
IgVH UM vs M 79/108 1.8 0.6-5.1 .29 IgVH UM vs M 79/108 1.9 0.7-5.3 .19 
CD38 ≥ 30% vs < 30% 45/142 0.3 0.1-1.1 .06 CD38 ≥ 30% vs < 30% 45/142 0.3 0.1-1.2 .08 
 
SNP 6.0 array genomic lesions ≥ 4 vs < 4 17/170 19.5 3.9-97 < .01 SNP 6.0 array genomic lesions ≥ 4 vs < 4 17/170 18 4-81 < .01 
Del17p or del11q present vs not 28/159 0.8 0.2-3.7 .78 TP53 exon 2-10 mutated vs not 22/165 0.9 0.3-3.3 .89 
Rai stage I-IV vs 0 90/97 1.1 0.5-2.7 .8 Rai stage I-IV vs 0 90/97 1.1 0.5-2.7 .8 
ZAP70 ≥ 20% vs < 20% 80/107 0.6 0.2-1.7 .3 ZAP70 ≥ 20% vs < 20% 80/107 0.6 0.2-1.6 .26 
IgVH UM vs M 79/108 1.2 0.4-3.8 0.78 IgVH UM vs M 79/108 1.2 0.4-3.8 .8 
CD38 ≥ 30% vs < 30% 45/142 0.4 0.1-1.6 .2 CD38 ≥ 30% vs < 30% 45/142 0.4 0.1-1.5 .2 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal